Re: Chemohormonal Therapy in Metastatic Hormone-sensitive Prostate Cancer
Section snippets
Conflicts of interest
The author has nothing to disclose.
References (2)
- et al.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open label, phase 3 trial
Lancet Oncol
(2013) - et al.
Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first overall survival results from STAMPEDE (NCT00268476) [abstract 5001]
J Clin Oncol
(2015)
Cited by (0)
Copyright © 2015 Published by Elsevier B.V.